© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Cyclo Therapeutics, Inc. (CYTH) shows an Average True Range (ATR) of 0.08 and an Enterprise Value of 29.12M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into CYTH's underlying financial health and market activity.
Cyclo Therapeutics, Inc. (CYTH) technical indicators as of January 1, 2026: the SMA 20 is 1.45%, SMA 50 at -8.57%, and SMA 200 at -15.88%. The RSI 14 value is 47.9, suggesting its current momentum. These technical analysis signals help assess CYTH's price trends and potential future movements.
Cyclo Therapeutics, Inc. (CYTH) stock performance overview as of January 1, 2026: The 52-week high is $1.45 (currently -59.74% below), and the 52-week low is $0.58 (currently 31.02% above). Over the past year, CYTH's performance is N/A, compared to the S&P 500's 12.29% change.
According to market data, Cyclo Therapeutics, Inc. (CYTH) stock's recent performance metrics show that over the last month, CYTH is -6.29%, with a Year-to-Date (YTD) performance of 22.14%. Over the past year, the stock has seen a N/A change. These figures summarize CYTH's price movements across various periods, reflecting its historical returns.
According to current financial data, CYTH stock's P/E (TTM) ratio is -1.40, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for CYTH, including P/S (66.10), P/B (-1.54), and P/FCF (-1.48), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.